- Home
- DIAX vs IMNM Comparison
DIAX vs IMNM Comparison
Compare DIAX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- IMNM
- Stock Information
- Founded
- DIAX 2005
- IMNM 2006
- Country
- DIAX United States
- IMNM United States
- Employees
- DIAX N/A
- IMNM N/A
- Industry
- DIAX Finance Companies
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- DIAX Finance
- IMNM Health Care
- Exchange
- DIAX Nasdaq
- IMNM Nasdaq
- Market Cap
- DIAX 552.4M
- IMNM 585.5M
- IPO Year
- DIAX N/A
- IMNM 2020
- Fundamental
- Price
- DIAX $15.52
- IMNM $10.17
- Analyst Decision
- DIAX
- IMNM Strong Buy
- Analyst Count
- DIAX 0
- IMNM 5
- Target Price
- DIAX N/A
- IMNM $28.60
- AVG Volume (30 Days)
- DIAX 96.6K
- IMNM 881.8K
- Earning Date
- DIAX 01-01-0001
- IMNM 11-13-2024
- Dividend Yield
- DIAX 7.93%
- IMNM N/A
- EPS Growth
- DIAX N/A
- IMNM N/A
- EPS
- DIAX N/A
- IMNM N/A
- Revenue
- DIAX N/A
- IMNM $10,129,000.00
- Revenue This Year
- DIAX N/A
- IMNM N/A
- Revenue Next Year
- DIAX N/A
- IMNM N/A
- P/E Ratio
- DIAX N/A
- IMNM N/A
- Revenue Growth
- DIAX N/A
- IMNM N/A
- 52 Week Low
- DIAX $12.80
- IMNM $8.97
- 52 Week High
- DIAX $15.12
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- DIAX 63.15
- IMNM 42.41
- Support Level
- DIAX $14.66
- IMNM $9.24
- Resistance Level
- DIAX $15.17
- IMNM $11.06
- Average True Range (ATR)
- DIAX 0.19
- IMNM 0.73
- MACD
- DIAX 0.06
- IMNM -0.03
- Stochastic Oscillator
- DIAX 100.00
- IMNM 39.41
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.